Health Care
Gilead's Quad Pill for AIDS May Overtake Atripla Sales, COO Milligan Says Gilead Sciences Inc., the world’s
biggest maker of AIDS medicines, will begin three final-stage
tests in 2010 for a four-drug combination pill against HIV that
has the potential to generate $4 billion a year by 2014.
Amgen's Denosumab Helps Bones of Prostate Cancer Patients More Than Rival Amgen Inc.’s experimental drug
denosumab reduced the rate of fractures in patients with
prostate cancer, a use that may help the drug gain a broad
market as a bone-strengthening treatment.
Biogen Fourth-Quarter Profit Rises on Sales of Multiple Sclerosis Drugs Biogen Idec Inc., the world’s largest
maker of medicines for multiple sclerosis, said fourth-quarter
profit jumped 48 percent, helped by higher sales of its fastest-
growing drug, Tysabri.
Stomach-Band Weight-Loss Surgery May Help Severely Obese Teens, Study Says Weight-loss surgery was more
effective at slimming severely obese teens and improving their
health than two years of diet and exercise, a study found.
AstraZeneca's Crestor Cleared by U.S. to Prevent Heart Attacks, Stroke AstraZeneca Plc’s widely used
cholesterol-lowering drug Crestor was approved by U.S.
regulators to prevent heart attacks and strokes for a broader
group of patients, the Food and Drug Administration said on its
Web site.
ChemGenex Falls in Sydney After FDA Questions Data on Leukemia Treatment ChemGenex Pharmaceuticals Ltd., the
Australian drugmaker seeking to sell its first drug, fell the
most in more than seven years in Sydney trading after the U.S.
Food and Drug Administration questioned the clinical
significance of the medicine.
Pfizer, Medivation Drug May Help Memory in Huntington's Disease Patients A 27-year-old hay fever treatment
being studied by Pfizer Inc. and Medivation Inc. for Alzheimer’s
disease may also help patients with Huntington’s disease.
Cochlear Forecasts 15% Annual Profit Growth on New Products, Cost Measures Cochlear Ltd., maker of the world’s
best-selling hearing implant, forecast full-year profit growth
of at least 15 percent on sales of new products. The shares rose
the most in seven weeks.
Richter Fourth-Quarter Nett Beats Forecasts on Higher Russian, U.S. Sales Net income at Gedeon Richter Nyrt.,
Hungary’s biggest drugmaker, beat analysts’ expectations on
rising sales in Russia and the United States.